文献速递炎症性肠病

突破治疗天花板:需要付出哪些努力

Breaking Through the Therapeutic Ceiling: What Will It Take?
PubMed 文献 · Gastroenterology · 2022-01-04

本文讨论炎症性肠病患者启动新治疗时疗效不确定、缓解率仍不普及的现状,提出需从早期诊断与初始管理、治疗分层与应答监测、临床试验设计及联合治疗药物选择等方面改进,以充分利用新治疗选择并打破治疗天花板。

要点

  • 炎症性肠病新治疗下患者缓解仍远非普遍体验,存在疗效「玻璃天花板」。
  • 需改进早期诊断与初始管理、治疗分层与应答监测以提升长期健康相关生活质量。
  • 需改进临床试验设计与联合治疗药物选择,以充分利用新治疗选择。

核心结论

  • 需在早期诊断与初始管理、治疗分层与应答监测、临床试验设计与联合治疗药物选择等多方面采取措施,才能充分利用新治疗选择并打破治疗天花板。

研究设计与样本

  • 本文为综述,讨论炎症性肠病治疗中需改进的多个领域及所需步骤。

主要发现

  • 炎症性肠病患者启动新治疗时疗效存在不确定性,缓解仍远非普遍体验。
  • 表面上存在「玻璃天花板」制约着所有患者实现最大长期健康相关生活质量的目标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes for patients starting a new treatment for inflammatory bowel disease are characterized by uncertainty of treatment response. Although it is natural to hope that new treatments will be characterized by better efficacy, remission is still far from a universal experience for patients living with inflammatory bowel disease. At times, an apparent "glass ceiling" appears to constrain progress toward a goal of maximal long-term health care-related quality of life for all. There are a number of areas that can and should be addressed if we are to make significant progress. These range from improved early diagnosis and initial management through better treatment stratification and response monitoring, to improvements in clinical trial design and selection of drugs in combination therapies. In this article, we discuss the steps required in all of these areas to make best use of new therapeutic options and shatter the glass ceiling.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Raine T, Danese S. Breaking Through the Therapeutic Ceiling: What Will It Take? Gastroenterology. 2022. PMID: 34995533. doi:10.1053/j.gastro.2021.09.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。